Apart from attenuating hyperinsulinemia or metabolic disorders in vivo and thus inhibiting insulin- or metabolite-dependent proliferative effects by both metformin and liraglutide [35,36], these two drugs also have direct anti-tumor effects in the in vitro studies [13,21,22,32]. The gene discussed is INS; the disease is metabolic disease.